Thanks for all of the info... much appreciated.
So, would it be too much to assume that the run-up could begin someday next week and ultimately bring us north of $3.50 before data?
So, given this new partnership, how does everyone believe a run-up to data will occur?
We seem to have built support around 2.90. When will the run-up from here begin and does the partnership place a new level on the magnitude of a potential run-up to data?
See full article with links at: http://biojaxusa.blogspot.com/
How much are Athersys shares worth ahead of the data release? It's certainly believed to be higher than the current trade area by many. Will 2015 be a repeat of 2014, the question on may investors minds? The science seems to support the opposite. Edison Investment Research has some valuation comments here: Athersys - Poised for pivotal stroke data. Obviously plugging in the formula Edison's using - a successful showing for MultiStem in the coming data release would value the stock at about $15.40 per share.
If the Edison price targets mentioned above seem high to investors - think again! Osiris shares reached a per share price of $27.40 on August 14, 2013 related to news surrounding its then adult stem cell program using an apparently inferior cell. Investors should also look at Alnylam, Pharmaceuticals, Inc. (NASDAQ: ALNY) and read here: Athersys, Inc.The Next Alnylam Pharmaceuticals, Inc. The fact is Alnylam an RNAi technology company has a great deal of interest in stem cells for a reason. To date Alnylam has marketed nothing!
The sole purpose for their existence is to provide support when needed for Cramer's hedge fund buddies. In other words: unbridled manipulation.
Potential new investor here. Thanks for all of the information!
When is the MRI data due out or expected? This quarter? First half of year? TIA!
We will break through the psychological $5 barrier shortly.
Count on it!
Just a thought.
Form 8-K for IDERA PHARMACEUTICALS, INC.
Entry into a Material Definitive Agreement, Other Events, Financial S
Item 1.01. Entry into a Material Definitive Agreement
On February 12, 2015, Idera Pharmaceuticals, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman, Sachs & Co. and J.P. Morgan Securities LLC, as representatives of the several underwriters (collectively, the "Underwriters"), related to an underwritten public offering of 20,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The public offering price for the Common Stock is $3.75 per share. The underwriters have agreed to purchase the shares pursuant to the Underwriting Agreement at a price of $3.525 per share. The Company has also granted to the Underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock at the same price per share. All of the shares in the offering are to be sold by the Company.
The Common Stock will be issued pursuant to a prospectus supplement dated February 12, 2015 and an accompanying base prospectus dated May 22, 2014 that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission, which became effective May 22, 2014 (File No. 333-195896). The Company expects that the closing of the sale of the Common Stock will take place on February 19, 2015, subject to the satisfaction of customary closing conditions.
A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to Exhibit 1.1.
A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the validity of the Common Stock to be issued in the offering is attached as Exhibit 5.1 hereto.
Item 8.01. Other Even
J&E, in just a few paragraphs, how would you compare and contrast ADXS and ZIOP from a technical solution perspective and from a business perspective (e.g. PPS appreciation potential). TIA!